NA
LENZ

NewEdge Advisors’s LENZ Therapeutics LENZ Stock Holding History

NewEdge Advisors’s Portfolio LENZ Stock Details LENZ Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$1.01K Hold
110
– – ﹤0.01% 3905
2025
Q4 		$1.76K Hold
110
– – ﹤0.01% 3907
2025
Q3 		$5.13K Buy
+110
New +$4.04K ﹤0.01% 3526

Other funds holding LENZ

RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
AWG
Alpha Wave Global New York $791M AUM 113.77% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
VVM
Versant Venture Management San Francisco, California $141M AUM 190.82% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Squarepoint
Squarepoint New York $85.1B AUM 20.93% 1-Year Est. Return
Aberdeen Group
Aberdeen Group Edinburgh, United Kingdom $61.9B AUM 29.81% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
7IH
72 Investment Holdings Stamford, Connecticut $49.6M AUM 684.72% 1-Year Est. Return

NewEdge Advisors's LENZ Position: Q1 2026 in Review

NewEdge Advisors held its LENZ Therapeutics (LENZ) position steady in Q1 2026 at 110 shares worth $1.01K. The position accounts for ﹤0.01% of the portfolio, ranked #3905.

NewEdge Advisors first reported a position in LENZ in Q3 2025 and has held it in 3 quarters since. The position peaked at $5.13K in Q3 2025. 145 funds tracked by Wall St. Rank hold LENZ as of Q1 2026.

  • NewEdge Advisors held 110 shares of LENZ Therapeutics worth $1.01K as of Q1 2026.
  • NewEdge Advisors left its LENZ Therapeutics share count unchanged in Q1 2026.
  • LENZ Therapeutics made up ﹤0.01% of NewEdge Advisors's portfolio in Q1 2026, its #3905 holding.
  • NewEdge Advisors first reported a position in LENZ Therapeutics in Q3 2025 and has held it in 3 quarters since.
  • NewEdge Advisors's LENZ Therapeutics position peaked at $5.13K in Q3 2025.
  • 145 funds tracked by Wall St. Rank held LENZ Therapeutics as of Q1 2026.

Based on NewEdge Advisors's 13F filing for Q1 2026, filed 18 May 2026.